



Polo-like kinase 1 regulates immune synapse assembly and cytotoxic T cell function by driving microtubule dynamics

This is a pre print version of the following article:

Original:

Zevolini, F., Onnis, A., Khazen, R., Müller, S., Marotta, G., Valitutti, S., et al. (2024). Polo-like kinase 1 regulates immune synapse assembly and cytotoxic T cell function by driving microtubule dynamics. JOURNAL OF CELL SCIENCE, 137(5) [10.1242/jcs.261476].

Availability:

This version is available <http://hdl.handle.net/11365/1256214> since 2024-10-31T09:09:27Z

Published:

DOI:10.1242/jcs.261476

Terms of use:

Open Access

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. Works made available under a Creative Commons license can be used according to the terms and conditions of said license.

For all terms of use and more information see the publisher's website.

(Article begins on next page)

1 **Polo-like kinase 1 regulates immune synapse assembly and cytotoxic T cell function**
2 **by driving microtubule dynamics**

3

4 Fabrizia Zevolini¹, Anna Onnis¹, Roxana Khazen², Sabina Müller², Giuseppe Marotta³,
5 Salvatore Valitutti², Francesca Finetti^{1#} and Cosima T Baldari^{1#}

6

7 ¹Department of Life Sciences, University of Siena, Siena, Italy; ²INSERM U1037, Centre de
8 Recherche en Cancérologie de Toulouse (CRCT), Toulouse, France; ³Siena University
9 Hospital, Siena, Italy.

10

11 #shared senior authorship

12

13 Corresponding authors: Dr. Francesca Finetti, Department of Life Sciences, University of
14 Siena, Via Aldo Moro 2, 53100 Siena, Italy, tel +39-0577-232427, email finetti4@unisi.it; Dr.
15 Cosima T Baldari, Department of Life Sciences, University of Siena, Via Aldo Moro 2, 53100
16 Siena, Italy, tel +39-0577-234400, email cosima.baldari@unisi.it

17

18 Running title: PLK1 regulates CTL polarization

19

20 Keywords: immune synapse / cytotoxic T cell / centrosome / microtubules / PLK1

21

22 **Summary statement**

23 The mitotic kinase Polo-like kinase 1 promotes centrosome polarization to the immune
24 synapse in cytotoxic T cells by coupling TCR signaling to microtubule dynamics

25

26 **Abstract**

27

28 Elimination of virally infected or tumoral cells is mediated by cytotoxic T cells (CTL). Upon
29 antigen recognition CTLs assemble a specialized signaling and secretory domain at the
30 interface with their target, the immune synapse (IS). During IS formation CTLs acquire a
31 transient polarity, marked by re-orientation of the centrosome and microtubule cytoskeleton
32 toward the IS, thus directing the transport and delivery of the lytic granules to the target cell.
33 Based on the implication of the kinase Aurora-A in CTL function we hypothesized that its
34 substrate, the mitotic regulator Polo-like kinase 1 (PLK1), may participate in CTL IS
35 assembly. We demonstrate that PLK1 is phosphorylated upon TCR triggering and polarizes
36 to the IS. PLK1 silencing or inhibition results in impaired IS assembly and function, as
37 witnessed by defective synaptic accumulation of TCRs as well as compromised centrosome
38 and lytic granule polarization to the IS, resulting in impaired target cell killing. This function
39 is achieved by coupling early signaling to microtubule dynamics, a function pivotal for CTL-
40 mediated cytotoxicity. These results identify PLK1 as a new player in CTL IS assembly and
41 function.

42 **Introduction**

43

44 Cytotoxic T cells (CTL) are the arm of adaptive immunity specialized in the elimination of
45 virally infected or tumoral cells. To achieve this function CTLs have evolved three
46 complementary mechanisms that function sequentially to allow for the serial killing of
47 cognate targets. The first involves the lytic granules (LG), which are specialized secretory
48 lysosomes enriched in the pore-forming toxin perforin (Prf) and the proteolytic enzymes
49 granzymes (Gzm) packed on a serglycin scaffold to form a dense core that is solubilized
50 upon LG exocytosis. Gzms are then delivered to cell targets through pores formed by Prf
51 polymerization to orchestrate their apoptotic demise (Cassoli and Baldari, 2022; McKenzie
52 and Valitutti, 2023). The second, which is essential for the sustained killing activity of CTLs
53 when their LG stores become exhausted, is mediated by the death receptor ligand FasL,
54 that triggers the apoptotic cascade initiated by caspase 8 through interaction with Fas on
55 target cells (Green and Llambi, 2015; Cassoli and Baldari, 2022). A third mechanism that
56 has been recently discovered involves the release of supramolecular attack particles
57 (SMAP), autonomous killing entities that are composed of a core containing Prf and Gzms
58 enclosed in a non-membranous glycoprotein shell (Balint et al., 2020) and stored in a
59 different type of LG, the multicore cytotoxic granule (Chang et al., 2022; Cassoli and Baldari,
60 2022).

61

62 CTL-mediated killing requires the assembly of the immune synapse (IS), a specialized
63 signaling and secretory platform that forms at the cell target interface (De La Roche et al.,
64 2016). TCR interaction with MHC-bound cognate peptide antigen on the target cell surface
65 triggers a signaling cascade that promotes the translocation of the centrosome and
66 associated microtubule cytoskeleton beneath the synaptic membrane, resulting in the
67 acquisition by the CTL of a transient polarity (Gomez and Billadeau, 2008; Huse et al., 2013).
68 This polarity is essential for the directional transport of the LGs and FasL-enriched vesicles
69 towards the target cell and their precise delivery at the IS, thus ensuring the selective killing
70 of the cognate target.

71

72 A tight interplay of the tubulin and actin cytoskeletons coordinates the movement of the
73 centrosome towards the IS, with microtubule (+) ends interacting with F-actin at the IS
74 periphery with the assistance the adaptors IQ-GAP, ezrin and Cdc42IP (Banerjee et al.,
75 2007; Gorman et al., 2012; Ilani et al., 2007). Regulators of microtubule and actin dynamics,

76 including the dynein/dynactin motor, the microtubule end-binding protein EB1, the small
77 GTPase Rac1, the formins mDia and INF2, and the histone deacetylase HDAC6 also
78 contribute to this process (Andrés-Delgado et al., 2013; Bouchet et al., 2016; Gomez and
79 Billadeau, 2008; Martín-Cófreces et al., 2012; Sanchez et al., 2019; Serrador et al., 2004).
80 Centrosome positioning at the IS center is paralleled by F-actin clearance to leave an actin-
81 poor region that facilitates LG exocytosis (Ritter et al., 2015). The signals that regulate
82 centrosome polarization in response to TCR triggering are as yet only partly defined. PLC γ
83 activation downstream of early TCR signaling has been identified as a key initiating event.
84 Diacyl glycerol produced by PLC γ at the IS center acts as a polarity determinant to attract
85 the atypical PKCs such as ζ (Huse et al., 2013). These kinases orchestrate the process of
86 centrosome translocation through phosphorylation of regulators of cytoskeleton dynamics
87 such as myosin II, that interacts with the dynein/dynactin complex to provide the pulling
88 forces required for centrosome movement (Liu et al., 2013).

89
90 Interestingly, the mitotic serine-threonine kinase Aurora A (AurA) has been recently
91 implicated in the signaling events leading to IS formation in CD4⁺ T cells (Blas-Rus et al.,
92 2016). In mitotic cells AurA expression and activity peak in late G2, when the protein is
93 concentrated at centrosomes (Bischoff, 1998). During mitosis AurA regulates centrosome
94 and spindle dynamics by recruiting microtubule nucleation and stabilization factors (Sardon
95 et al., 2008). In non-dividing CD4⁺ T cells AurA is activated upon TCR stimulation and
96 modulates TCR signaling to regulate the growth of the microtubules arising from the
97 centrosome, thereby facilitating the polarized vesicular traffic that is essential for T cell
98 activation and effector function (Blas-Rus et al., 2016). Here we have investigated the role
99 of the mitotic kinase PLK1, a key substrate of AurA controlling centrosome and microtubule
100 dynamics during cell cycle progression (Joukov and De Nicolo, 2018), in CTL IS assembly.
101 We show that PLK1 is associated with the centrosome and is co-mobilized to the IS, where
102 a pool of active PLK1 associates with the synaptic membrane. We provide evidence that
103 PLK1 subserves AurA-dependent and -independent functions in CTLs, where it promotes
104 centrosome polarization to the IS and the downstream events leading to target cell killing by
105 coupling TCR signaling to microtubule growth. Our results identify PLK1 as a new player in
106 CTL IS assembly and effector function.

107 **Results**

108

109 **PLK1 is recruited to the CTL IS together with the centrosome and is activated in**
110 **response to TCR signaling**

111

112 PLK1 has been reported to localize at the centrosome in a variety of cell types (Colicino and
113 Hehnly, 2018), yet its localization in T lymphocytes is presently elusive. To address this
114 point we generated CTLs from peripheral blood CD8⁺ T cells freshly purified from healthy
115 donors and activated using beads coated with anti-CD3 and anti-CD28 mAbs in the
116 presence of IL-2. Under these conditions CD8⁺ T cells differentiate to fully functional CTLs
117 by day 5-7 (Onnis et al., 2023).

118

119 Immunoblot analysis showed that PLK1 is expressed in freshly purified CD8⁺ T cells and
120 that its expression is increased during their differentiation to CTLs (Fig.1A). To determine
121 the intracellular localization of PLK1 in CTLs we carried out a confocal microscopy analysis
122 of CTLs co-stained for PLK1 and either pericentriolar material 1 (PCM1), a centriolar satellite
123 protein that is responsible for PLK1 recruitment to the pericentriolar matrix (Wang et al.,
124 2013), or the centrosome marker γ -tubulin. Similar to other cell types, PLK1 was found to
125 localize at the centrosome in CTLs (Fig.1B). PLK1 also co-localized with the centrosome in
126 CMV-specific T cell clones (Fig.S1A,B) and in other T cell settings, including Jurkat T cells
127 and freshly purified peripheral blood CD4⁺ T cells (Fig.S2A). AurA also displayed a
128 centrosomal localization in CTLs (Fig.S3A,B), as previously reported for CD4⁺ T cells (Blas-
129 Rus et al., 2016).

130

131 To assess whether PLK1 could participate in centrosome dynamics during IS formation, we
132 carried out a similar co-localization analysis in conjugates of CTLs with Raji B cells pulsed
133 with a mix of staphylococcal superantigens (SAGs) allowing for the polyclonal activation of
134 T cells independently of antigen specificity. The analysis was carried out either 5 or 15
135 minutes after conjugate formation to visualize the events taking place during IS assembly
136 (De La Roche et al., 2016). PLK1, as well as AurA, were found to localize at the CTL
137 subsynaptic region in association with the centrosome as early as 5 min after conjugate
138 formation (Fig.1C; Fig.S3A,C). Similar results were obtained in antigen-specific conjugates
139 formed using CMV-specific CD8⁺ T cell clones (Fig.S1A,C). PLK1 co-polarized with the

140 centrosome to the IS also in Jurkat T cells and freshly purified peripheral blood CD4⁺ T cells
141 (Fig.S2B,C).

142

143 The kinase activity of PLK1 depends on its phosphorylation by AurA and its co-factor Bora
144 on the T-loop Thr210 residue (Bruinsma et al., 2013). Immunoblot analysis of the
145 phosphorylated, active form of PLK1 (pPLK1) revealed that, while pPLK1 was barely
146 detectable in unstimulated cells, there was a sharp increase in response to TCR
147 engagement, with the highest levels detected at the earliest time point analyzed (Fig.1D).
148 To assess the specific localization of activated PLK1 at the IS, we performed a confocal
149 microscopy analysis of pPLK1 in CTLs conjugated with either SAg-pulsed or unpulsed Raji
150 B cells. pPLK1 could be detected at the centrosome in conjugates formed both in the
151 absence of and in the presence of SAGs (Fig.1E). Additionally, pPLK1 was detectable at the
152 IS in SAg-specific conjugates (Fig.1E). Hence PLK1 polarizes to the IS in association with
153 the centrosome and a pool of its active form accumulates at the synaptic membrane,
154 suggesting a potential implication in CTL IS formation.

155

156

157 **PLK1 is required for IS formation and TCR signaling in CTLs**

158

159 IS formation is marked by the accumulation of TCR complexes at the central area of the T
160 cell interface with the APC. Two TCR pools, of which one associated with the plasma
161 membrane and the other with recycling endosomes, are sequentially recruited to the IS
162 following TCR engagement by cognate antigen, thereby ensuring sustained TCR signaling
163 (Soares et al., 2013). To investigate the potential role of PLK1 at the CTL IS we took
164 advantage of the highly selective ATP analogue BI2536, which inhibits PLK1 activity at low
165 nanomolar concentrations (Steehmaier et al., 2007). Confocal microscopy analysis of SAg-
166 specific CTL conjugates revealed that the synaptic accumulation of TCRs was impaired in
167 BI2536-treated CTLs, as assessed by labelling the CD3 ζ chain of the TCR complex (Fig.2A),
168 indicating that PLK1 is required for IS formation in CTLs. Similar results were obtained on
169 Jurkat and freshly purified peripheral CD4⁺ T cells (Fig.S2D,E). To rule out off-target effects
170 of BI2536, TCR accumulation at the IS was also analyzed on SAg-specific conjugates
171 formed with CTLs where PLK1 expression was silenced by RNA interference (Fig.2B). PLK1
172 KD CTLs recapitulated the defect observed in BI2536-treated CTLs (Fig.2C), supporting the
173 key role of PLK1 in IS formation. PLK1 blockade resulted in defective synaptic TCR

174 accumulation also in Jurkat T cells and freshly purified peripheral blood CD4⁺ T cells
175 (Fig.S2D,E).

176

177 The PLK1 upstream activator AurA has been implicated in early TCR signaling by promoting
178 the activatory phosphorylation and synaptic localization of the initiating kinase Lck in CD4⁺
179 T cells (Blas-Rus et al., 2016). To understand whether PLK1 may mediate this effect of AurA
180 in CTLs we imaged the active form of Lck, phosphorylated on Y394, in BI2536- treated CTLs
181 conjugated with SAg-pulsed Raji cells. A defect in the IS accumulation of active Lck was
182 observed in PLK1-inhibited CTLs (Fig.3A). Inhibition of Lck phosphorylation on Y394 in the
183 presence of BI2536 was also observed by immunoblot analysis of post-nuclear supernatants
184 from CTLs activated by antibody-mediated TCR cross-linking (Fig.3B). Consistent with this
185 defect, immunoblot analysis of the active forms of two proteins that participate at sequential
186 steps in the signaling cascade downstream of Lck, namely the transmembrane adaptor LAT
187 and the kinase Erk1/2 (Samelson, 2002), showed that BI2536 treatment led to an
188 impairment in TCR-dependent LAT and Erk phosphorylation (Fig.3C). The results indicate
189 that PLK1 regulates the TCR signaling cascade in CTLs, accounting for its requirement for
190 IS formation.

191

192

193 **PLK1 is required for centrosome and LG polarization to the IS and for CTL-mediated** 194 **killing**

195

196 Centrosome translocation toward the T cell interface with cognate APC occurs in response
197 to TCR engagement and in turn orchestrates the polarized recycling of endosome-
198 associated TCRs to the synaptic membrane (Das et al., 2004). In CTLs, centrosome
199 reorientation toward the IS, concomitant with the dynamic reorganization of the microtubule
200 cytoskeleton, ensures the polarized transport of LGs along the microtubules to the site of
201 contact and the release of their contents into the synaptic cleft (Douanne and Griffiths, 2021;
202 Kabanova et al., 2018). Confocal analysis of SAg-specific conjugates formed with BI2536-
203 treated CTLs showed an impairment in both centrosome and LG repositioning beneath the
204 IS membrane, as assessed by quantifying both the frequency of conjugates harboring
205 centrosome and LG polarization at the IS and their distance from the synaptic membrane
206 (Fig.4A,B,C). Similar results were obtained using PLK1 KD CTLs (Fig.4E,F) and a CMV-
207 specific CTL clone (Fig.S1D,E,F). Furthermore, LG convergence around the centrosome,

208 which occurs in preparation for their transport to the IS (Calvo and Izquierdo, 2021), was
209 impaired in BI2536-treated CTLs, as assessed by measuring the distance of individual
210 GzmB⁺ vesicles from the PCNT-1 positive compartment (Fig.4D). This defect was
211 recapitulated in PLK1 KD CTLs (Fig.4G). The inhibitory effect of BI2536 on centrosome
212 polarization was also observed in CMV-specific CTL clone (Fig.S1G), Jurkat and freshly
213 purified peripheral CD4⁺ T cells (Fig.S2D,E).

214

215

216 **PLK1 promotes microtubule growth in CTLs**

217

218 Upon TCR stimulation, microtubule filaments and microtubule motor proteins anchored at
219 the cell cortex at the CTL interface with its cell target provide the pulling forces for
220 centrosome translocation (Kuhn and Poenie, 2002). Microtubules are large polymers
221 composed of α/β -tubulin dimers that are endowed with an intrinsic polarity, with (-) ends
222 anchored to the centrosome to avoid rapid depolymerization and (+) ends characterized by
223 dynamic instability (Li and Gundersen, 2008). After centrosome polarization, microtubules
224 actively polymerize at the IS. Altering microtubule (+) end dynamics delays centrosome
225 reorientation and vesicular traffic to the IS (Hooikaas et al., 2020; Martín-Cófreces et al.,
226 2012), underscoring the importance of microtubule plasticity in the establishment of a
227 functional IS.

228

229 PLK1 plays a crucial role in orchestrating microtubule dynamics in cycling cells (Zitouni et
230 al., 2014). We hypothesized that the architecture of the microtubule cytoskeleton might be
231 altered in PLK1-inhibited CTLs. To address this point, we imaged control and BI2536-treated
232 CTLs plated under non-activating conditions (poly-L-lysine) and stained for α -tubulin.
233 Control CTLs displayed numerous thin microtubules radiating from the centrosome
234 (Fig.5A,B). When PLK1 activity was inhibited, microtubules organized in thick bundles that
235 in some cases appeared to originate in the cortical area (Fig.5A,B). To quantify this feature
236 we measured the skewness of pixel intensity, an amply validated method for the quantitative
237 detection of bundling of actin filaments and microtubules (Higaki, 2010; Higaki, 2017). The
238 skewness of the fluorescence intensity distribution becomes higher when the number of
239 pixels with high fluorescence intensity is increased, providing a quantitative and reliable
240 measurement of cytoskeleton bundling. BI2536-treated CTLs showed a higher skewness in

241 α -tubulin staining compared to control cells (Fig.5C), providing evidence that PLK1 is
242 involved in the regulation of the architecture of the microtubule cytoskeleton in CTLs.

243

244 Since microtubule dynamics regulates the polarization of the centrosome to the IS
245 (Stinchcombe and Griffiths, 2014), we asked whether the TCR signaling defect observed in
246 BI2536-treated CTLs under steady-state conditions may impact on microtubule growth
247 during IS assembly. CTLs were transiently transfected with a plasmid construct encoding
248 EGFP-tagged EB1, a protein that binds to the (+) end of growing microtubules (Nehlig et al.,
249 2017), and plated on glass-immobilized anti-CD3 mAb to induce centrosome polarization
250 and microtubule polymerization (Bunnell et al., 2002). The dynamics of microtubule growth
251 following CTL stimulation was tracked by EB1-EGFP live cell imaging and total internal
252 reflection fluorescence (TIRF) microscopy to improve spatial and time resolution (Dixit and
253 Ross, 2010) (Fig.5D). BI2536-treated EB1-EGFP transfected CTLs displayed altered
254 microtubule dynamics (Fig.5D-F; Movies 1,2). In particular, the number and length of each
255 segment, identified as the portion of each EB1-EGFP labelled track with a constant
256 trajectory, were decreased in CTLs following BI2536 treatment, showing that the
257 directionality of newly formed tracks was affected when PLK1 was inhibited (Fig.5D-F).
258 Furthermore, the growth of microtubules was slower in BI2536-treated CTLs compared to
259 control cells (Fig.5D-F). Taken together, these results indicate that PLK1 regulates
260 microtubule dynamics during IS assembly in CTLs.

261

262

263 **PLK1 is required for efficient CTL-mediated killing**

264

265 Rapid LG secretion upon target cell encounter can occur in the absence of centrosome
266 translocation towards the IS membrane (Bertrand et al., 2013). Yet, the IS polarization of
267 the CTL lytic machinery ensures the prolonged and confined secretion of lytic molecules
268 onto the target cell, as demonstrated by the reduction in cytotoxicity when centrosome
269 reorientation is delayed or defective (De La Roche et al., 2013; Jenkins et al., 2014; Tsun et
270 al., 2011). To test the outcome of the IS defects associated with PLK1 inhibition on the killing
271 capability of CTLs we performed a time course analysis of fluorescent calcein release by
272 SAg-pulsed target cells induced by either BI2536-treated or untreated CTLs. In this assay
273 target cells are loaded with the cell-permeant dye calcein AM, that becomes fluorescent
274 following hydrolyzation by intracellular esterases and is released upon cell death (Chang et

275 al., 2018). Consistent with the role of PLK1 in TCR signaling and IS assembly, the killing
276 capability of CTLs was impaired at every effector:target cell ratio (E:T) tested when PLK1
277 activity was inhibited (Fig.6A). Similar results were obtained using PLK1 KD CTLs (Fig.6B).
278 Hence PLK1 contributes to CTL-mediated killing through its ability to regulate IS assembly.
279

280 Discussion

281

282 The role of mitotic kinases in non-cycling cells has been as yet poorly investigated. Here we
283 show that PLK1, known to regulate centrosome duplication and microtubule dynamics
284 during mitosis (Joukov and De Nicolo, 2018), is required for IS assembly in non-cycling T
285 cells. We provide evidence that PLK1 subserves a dual role in this process, participating in
286 the TCR signaling cascade and modulating microtubule dynamics. Both these functions
287 converge on centrosome polarization towards the T cell contact with its cognate target, a
288 key step in the formation of a functional IS. In CTLs, the failure of the centrosome to polarize
289 to the IS following pharmacological inhibition or silencing of PLK1 led to impaired LG
290 translocation towards the target cell and defective target cell killing, identifying PLK1 as a
291 new regulator of CTL function.

292

293 Key players in early TCR signaling, including the kinases Lck and ZAP-70 and the adaptors
294 LAT and SLP-76, are required for centrosome polarization (Kuhné et al., 2003; Lowin-Kropf
295 et al., 1998). How these early events translate into the physical movement of the centrosome
296 towards the subsynaptic region has been in part elucidated. Diacylglycerol locally produced
297 at the IS by PLC γ acts as a polarity cue for the centrosome through the recruitment of
298 members of the novel and atypical PKC subfamilies (Huse, 2012). TCR signaling also
299 promotes the synaptic recruitment of the dynein-dynactin complex that has been proposed
300 to provide pulling forces on the microtubules radiating from the centrosome (Liu et al., 2013).
301 Additionally, actin filaments that polymerize at the IS periphery interact with these
302 microtubules to provide tension for centrosome translocation (Calvo and Izquierdo, 2021).
303 The mechanism linking the novel and atypical PKCs to the cytoskeletal elements that
304 provide the pulling forces remains to be fully characterized. The implication of PLK1 in TCR
305 signaling, starting with the activation of the initiating kinase Lck, is likely to account, at least
306 in part, for the defect in centrosome polarization observed in PLK1-inhibited or -depleted T
307 cells. The TCR-dependent recruitment of a pool of phosphorylated PLK1 to the IS places it
308 in a strategic position to regulate the early signaling events that orchestrate centrosome
309 polarization.

310

311 How PLK1 regulates the activity of Lck remains to be determined. The activity of Lck is tightly
312 controlled by the phosphorylation status of Y394 and Y505. While full activation requires
313 Y505 dephosphorylation by the transmembrane tyrosine phosphatase CD45 and Y394

314 autophosphorylation, serine phosphorylation contributes to fine-tuning its activity (Rossey et
315 al., 2012). The threonine/serine kinase Erk has been shown to phosphorylate Lck on S59
316 under conditions of strong TCR stimulation, which prevents the recruitment of the
317 phosphatase SHP-1 that disables Lck by dephosphorylating Y394, thereby sustaining TCR
318 signaling (Štefanová et al., 2003). PLK1 could be hypothesized to participate directly or
319 indirectly in such regulatory circuitry. As the search for PLK1 substrates has been mainly
320 restricted to the context of mitosis, extending these studies to non-cycling cells may provide
321 new insights into the non-mitotic functions of this kinase.

322

323 In mitotic cells PLK1 regulates microtubule dynamics by promoting microtubule nucleation
324 at the centrosome through phosphorylation of PCM components, such as SPD-5 in *C.*
325 *elegans*, that recruit the γ -tubulin ring complex (γ -TuRC) (Ohta et al., 2021). Additionally,
326 PLK1 regulates microtubule-based microtubule nucleation in human cells during mitotic
327 spindle formation by promoting the interaction of the γ -TuRC recruitment protein, Nedd1,
328 with microtubule-bound Augmin (Johmura et al., 2011). PLK1 has also been implicated in
329 the control of microtubule stability in *D. melanogaster* and mammalian cells through its ability
330 to modulate the activity of the microtubule-associated protein CLASP and the (+) end
331 microtubule motor Kif13 (Moriwaki and Goshima, 2016). Consistent with a role for PLK1 in
332 microtubule dynamics, the rate and extent of microtubule growth has been shown to
333 decrease in PLK1-inhibited human breast adenocarcinoma MCF-7 cells, concomitant with
334 an increase in microtubule acetylation (Rashid et al., 2020). Microtubule dynamics is
335 essential for centrosome polarization to the IS. Genetic depletion of regulators of
336 microtubule growth or stability in T cells, such as the microtubule-binding proteins EB1 and
337 stathmin (Filbert et al., 2012; Martín-Cófreces et al., 2012; Zyss et al., 2011) or modulation
338 of tubulin acetylation through HDAC6 overexpression (Serrador et al., 2004), have been
339 associated with impairment or delay in centrosome polarization to the IS and defective T cell
340 function. It is noteworthy that, while faster rates of microtubule growth translate to increased
341 traction forces that improve the killing activity of CTLs (Pathni et al., 2022), microtubule
342 overgrowth, as observed in T cells depleted of the kinesin Kif21B, also leads to a similar
343 defect (Hooikaas et al., 2020), underscoring the notion that microtubule dynamics must be
344 tightly controlled during the complex process of centrosome translocation to the IS and the
345 subsequent polymerization of new microtubules from the repositioned centrosome. Our
346 finding that PLK1 regulates microtubule growth during IS assembly suggests that its ability
347 to promote centrosome polarization might not be limited to its role in TCR signaling but also

348 depend on a more direct role in microtubule nucleation at the centrosome. Interestingly, the
349 *Xenopus* Polo-like kinase Plx1 has been reported to regulate the function of stathmin/Op18
350 (Budde et al., 2001). Additionally, in pre-mitotic ciliated cells PLK1 promotes cilium
351 disassembly by phosphorylating HDAC6, thereby promoting microtubule deacetylation and
352 disassembly (Wang et al., 2013). The finding that EB1, stathmin and HDAC6 are recruited
353 to the IS in T cells (Filbert et al., 2012; Martín-Cófreces et al., 2012; Serrador et al., 2004)
354 provides a potential direct link between PLK1 and microtubule dynamics during IS assembly.
355

356 It is noteworthy that the effects of PLK1 inhibition or depletion in T cells reported here do not
357 completely phenocopy the effects elicited by blockade or depletion of its upstream regulator
358 AurA in CD4⁺ T cells (Blas-Rus et al., 2016). Both associate with the T cell centrosome and
359 localize at the IS, where a pool of either active kinase can be found. They are both required
360 for Lck activation and early TCR signaling and for microtubule growth during IS formation.
361 However, a major difference is in their ability to promote centrosome translocation, which is
362 not affected in AurA-targeted T cells (Blas-Rus et al., 2016). While the study on AurA was
363 carried out on freshly purified CD4⁺ T cells and our study mainly on CD8⁺ cells differentiated
364 to CTLs, we found a similar inhibitory effect of PLK1 blockade on centrosome polarization
365 to the IS in freshly purified CD4⁺ T cells, as well as in the CD4⁺ T cell-derived Jurkat cell
366 line. This suggests that, while the AurA/PLK1 axis that regulates mitosis is operational during
367 IS assembly in non-cycling T cells, PLK1 does not only act as effector of AurA but also
368 subserves AurA-independent functions in this process.

369
370 Not surprisingly considering its key role in cell division, PLK1 is overexpressed in many types
371 of both solid and blood cancers (Iliaki et al., 2021). A plethora of studies have provided
372 evidence that targeting PLK1 using selective pharmacological inhibitors blocks the
373 proliferation of cancer cells and promotes their apoptosis, setting the basis for a number of
374 clinical trials (Gutteridge et al., 2016; Park et al., 2015; Strebhardt, 2010; Su et al., 2022;
375 Zeidan et al., 2020). Our finding that PLK1 is required for IS assembly, on which T cell
376 activation depends, highlights a potential drawback of PLK1-targeted therapies. The T cell
377 suppressive activity of a PLK1-specific inhibitor on the activation of alloreactive T cells in
378 acute graft-versus-host disease (Hooikaas et al., 2020), while highlighting the potential
379 therapeutic benefits of targeting PLK1 in this disease context, underscores the importance
380 of investigating the immune functions of cancer patients undergoing PLK1-directed
381 therapies.

382 **Materials and methods**

383

384 **Cells, T cell transfectants, antibodies**

385 CD8⁺ and CD4⁺ T cells were isolated from peripheral blood of anonymous healthy donors
386 obtained from the Siena University Hospital blood bank. The study was approved by the
387 local ethics committee (Siena University Hospital). Informed consent was obtained from
388 blood donors by the physician in charge of the Siena University Hospital blood bank.
389 Samples were anonymized before distribution. Primary CD8⁺ and CD4⁺ T cells were isolated
390 by negative selection through either RosetteSep™ Human CD8⁺ T Cell Enrichment Cocktail
391 (StemCell technologies, Vancouver, Canada) or RosetteSep™ Human CD4⁺ T Cell
392 Enrichment Cocktail (StemCell technologies, Vancouver, Canada) and centrifugation over
393 a buoyant density medium (Lympholyte Cell Separation Medium, Euroclone, Milan, Italy).
394 Immediately after isolation, CD8⁺ and CD4⁺ T cells were resuspended in RPMI 1640 with 25
395 mM HEPES (Sigma-Aldrich, St. Louis, Missouri, USA), supplemented with 10% BCS (Bovine
396 Calf Serum, Hyclone, Logan, Utah, USA) inactivated at 56 °C for 30 minutes, 20 U/mL
397 Penicillin (Sigma-Aldrich, St. Louis, Missouri, USA) and 1X non-essential amino acids (MEM
398 non-essential amino acids solution 100X, Gibco, Waltham, Massachusetts, USA). Cell
399 cultures were maintained at 37 °C and 5% CO₂. Freshly isolated CD8⁺ T cells were
400 differentiated *in vitro* to CTLs by incubation for 48 h with anti-CD3/CD28 coated magnetic
401 beads (Dynabeads Human T-activator CD3/CD28, Gibco, Waltham, Massachusetts, USA)
402 for cell expansion and activation and 50 U/mL of IL-2 (human Interleukin-2, Miltenyi Biotech,
403 Bergisch Gladbach, Germany) for cell proliferation and differentiation. Mature CTLs (days 5
404 to 7 of differentiation) were used for the experiments (Onnis *et al.*, 2022). Freshly isolated
405 CD4⁺ T cells were immediately used for the assays.

406 To generate CTL clones, CD8⁺ T cells specific for the VLAELVKQI peptide of the
407 cytomegalovirus protein pp65 were single cell sorted into 96-U-bottom plates using a BD
408 FACS Aria II cell sorter using tetramer staining. Cells were cultured in RPMI 1640 medium
409 supplemented with 8% human AB serum (PAA), minimum essential amino acids, HEPES
410 and sodium pyruvate (Invitrogen), 100 IU/ml human rIL-2 and 50 ng/ml human rIL-15. CD8⁺
411 T-cell clones were stimulated in complete RPMI/HS medium containing 1 mg/ml PHA with
412 1 x 10⁶/ ml 35 Gy irradiated allogeneic peripheral blood mononuclear cells (isolated on Ficoll
413 Paque Gradient from buffy coats of healthy donors) and 1 x 10⁵/ ml 70 Gy irradiated EBV-
414 transformed B cells. Re-stimulation of clones was performed every 2 weeks. Blood samples
415 were collected and processed following standard ethical procedures (Helsinki protocol),

416 after obtaining written informed consent from each donor and approval for this study by the
417 local ethical committee (Comité de Protection des Personnes Sud-Ouest et Outremer II).
418 Other cells used were Raji B cells, EBV-transformed B cells (JY) and Jurkat T cells (ATCC,
419 Manassas, VA), maintained in RPMI 1640 supplemented with 7.5% BCS and 20 U/ml
420 Penicillin.

421 For RNAi-mediated PLK1 silencing CTLs were transiently transfected at day 6 of
422 differentiation using the Human T cell nucleofector kit and the program T-023 of the
423 Nucleofector II system (Amaxa Biosystems, Euroclone, Milan, Italy) for activated cells with
424 human PLK1-specific siRNAs (#4390824, s448) and negative control siRNA (#4390846)
425 (Invitrogen, Waltham, Massachusetts, USA) (150 ng/10⁶ cells). Cells were used 24 h post-
426 transfection. All samples were tested by immunoblotting to check the efficiency of PLK1
427 knockdown.

428 CTLs were transiently transfected with the pEGFP plasmid encoding the EB1-GFP fusion
429 protein (Addgene #17234, Watertown, Massachusetts, USA). Briefly, CTLs at 5 days of
430 differentiation were transiently transfected using the Human T cell nucleofector kit and the
431 program T-023 of the Nucleofector II system (Amaxa Biosystems, Euroclone, Milan, Italy)
432 for activated cells with 1 µg/10⁶ cells of pEGFP-EB1 plasmid. Transfected cells were gently
433 resuspended in the culture medium added with 500 U/ml IL-2 and analysed 24 h post-
434 transfection.

435 T cells were pre-treated with the PLK inhibitor BI2536 (Selleckchem, Houston, Texas, USA)
436 at the concentration of 100 nM in DMSO in serum-free medium for 3 h at 37°C and 5% CO₂
437 and used as such for the assays (Lénárt et al., 2007). Control samples were incubated with
438 the same amount of DMSO.

439 All primary commercial antibodies used in the assays are listed in Table 1, together with
440 information on the dilutions used for immunoblotting and immunofluorescence. Secondary
441 horseradish peroxidase (HRP)-labelled antibodies were purchased from Jackson
442 ImmunoResearch Laboratories (West Grove, Pennsylvania, USA) and Alexa Fluor 488- and
443 555-labeled secondary antibodies from ThermoFisher Scientific (Waltham, Massachusetts,
444 USA). IgG from OKT3 (anti-human CD3ε, IgG2) hybridoma supernatants was purified using
445 Mabtrap (Amersham Biosciences, Inc., Piscataway, NJ, USA) and titrated by flow cytometry.

446

447 **Conjugate formation, CTL activation on activating surfaces, immunofluorescence**
448 **and image analysis**

449 Conjugates between CD8⁺ T cells and superantigen-pulsed Raji B cells were carried out as
450 previously described (Cassoli et al., 2021). Raji B cells (used as APCs) were loaded with
451 10 µg/ml of a mix of Staphylococcal Enterotoxins A (SEA), B (SEB) and E (SEE) (Toxin
452 Technologies, Sarasota, Florida, USA) for 2 h at 37°C and labelled with 10 µM Cell Tracker
453 Blue for the last 20 min of the incubation with superantigens (SAGs). Conjugates of CTLs
454 with unpulsed Raji B cells were used as negative controls. SAg-pulsed or unpulsed Raji B
455 cells were mixed with CTLs (1:1) to allow conjugate formation at 37°C for the indicated time
456 points. Samples were seeded onto poly-L-lysine (Merck, Darmstadt, Germany)-coated slides
457 (ThermoFisher Scientific, Waltham, Massachusetts, USA). Alternatively, CTLs were
458 activated in the absence of target cells by plating on 5 µg/ml anti-CD3 antibody (clone
459 OKT3)(Bio Legend, San Diego, California, USA)-coated slides. Cells were fixed with either
460 methanol at -20°C for 10 min or 4% paraformaldehyde/PBS at room temperature for 15 min.
461 After washing with PBS, cells were stained with primary antibodies at 4°C overnight, and
462 then incubated at room temperature for 45 min with Alexa fluor 488- and 555-labeled
463 secondary antibodies and mounted with 90% glycerol/PBS.

464 Confocal microscopy was carried out on a Zeiss LSM700 microscope (Carl Zeiss, Jena,
465 Germany) using a 63x/1.40 oil immersion objective or a spinning disk confocal and super-
466 resolution microscope (CSU-W1-SoRA Nikon), with 100x/1.49 oil objective. 3D
467 deconvolution (Blind method, 20 iterations) and denoise were performed using the software
468 NIS Elements AR Nikon and applied to high-resolution images. Detectors were set to detect
469 the optimal signal below the saturation limits.

470 Co-localization analyses were performed on medial optical sections of single cells using
471 ImageJ and the JACoP plugin to calculate Mander's coefficient (Manders et al., 1992).
472 Mander's coefficients range from 0 to 1, corresponding to non-overlapping images and
473 100% co-localization between both images, respectively.

474 Polarization of CD3ζ, GzmB⁺ lytic granules and PLK1, and the translocation of the
475 centrosome to the IS, were based on the presence of the staining solely on the CTL:APC
476 contact site and were expressed as the percentage of conjugates with synaptic staining
477 *versus* the total number of conjugates analysed. The relative distance of the centrosome,
478 PLK1, AurA and individual GzmB⁺ vesicles from the contact site of CTLs with APCs or
479 individual GzmB⁺ vesicles from the centrosome was measured using ImageJ. The
480 recruitment index was calculated as the ratio of either CD3ζ or pPLK1 fluorescence intensity
481 at the synaptic area, which is manually defined at the CTL:APC contact site *versus* the entire
482 cell membrane, using ImageJ. The relative pPLK1 fluorescence at the centrosome was

483 calculated over a circular region defined from the point of PCM1 maximal intensity. The
484 skewness of the intensity distribution of α -tubulin was measured using Fiji, by calculating
485 the mean value of 3 different regions ($2 \times 3 \mu\text{m}$) for each cell, excluding the centrosomal area.

486

487 **Live cell imaging and analysis**

488 For TIRF microscopy, EB1-EGFP transfected CTLs were washed and seeded at 1.5×10^5
489 cells per well on $5 \mu\text{g/ml}$ anti-CD3 antibody (clone OKT3)-coated eight-well chambered
490 slides (Ibidi, Munich, Germany). Chambered slides were mounted on a heated stage within
491 a temperature-controlled chamber maintained at 37°C , and constant CO_2 concentrations
492 (5%). Cells were visualized using a CSU-W1-SoRA Nikon microscope coupled to
493 Photometrics BSI (Nikon) camera fitted with $100 \times / 1.49$ oil objective. Images were taken
494 every 300 ms for 3 minutes and time lapses were processed with the confocal software NIS
495 Elements AR Nikon. Images were equalized in intensity in time, denoised, background
496 corrected and then bright spots were detected and tracked.

497

498 **Cell lysis and Immunoblotting**

499 Cells (2×10^6 /sample) were stimulated with purified anti-human CD3 ϵ for the indicated time
500 at 37° . Cells were then lysed in 0.5% (v/v) Triton X-100 in 20 mM Tris-HCl (pH 8), 150 mM
501 NaCl in the presence of Protease inhibitor Cocktail Set III (Calbiochem®, Merck, Darmstadt,
502 Germany) and the phosphatase inhibitor sodium orthovanadate (Sigma-Aldrich, St. Louis,
503 Missouri, USA) for 5 min on ice. Protein extracts from post-nuclear supernatants were
504 quantified with the Quantum protein assay kit (Euroclone, Milan, Italy) and denatured in 4x
505 Bolt SDS sample buffer (Invitrogen, Waltham, Massachusetts, USA) supplemented with 10x
506 Bolt sample reducing buffer (Invitrogen, Waltham, Massachusetts, USA) for 5 min at 100°C .
507 Proteins ($10 \mu\text{g}$) were subjected to SDS-PAGE on Bolt Bis-Tris mini protein gels (Invitrogen,
508 Waltham, Massachusetts, USA) and transferred to nitrocellulose (GE HealthCare,
509 Euroclone, Milan, Italy) under wet conditions. Blocking was performed in 5% non-fat dry milk
510 in PBS containing 0.2% Tween 20 (Sigma-Aldrich, St. Louis, Missouri, USA). Membranes
511 were incubated in primary antibodies for 1-3 h at room temperature ($20\text{-}25^\circ\text{C}$) or overnight
512 at 4°C , followed by incubation with 20 ng/ml HRP-conjugated secondary antibodies
513 (Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania, USA) for 45 min at
514 room temperature. Secondary antibodies were detected using SuperSignal west pico plus
515 chemiluminescent substrate (Life Technologies, Waltham, Massachusetts, USA). For
516 quantification, immunoblot membranes were scanned using Alliance Q9-Atom

517 chemiluminescence imaging system (Uvitec, Cambridge, UK), and densitometric levels
518 were measured using ImageJ software (National Institutes of Health, USA).

519

520 **Real-time calcein release-based killing assay**

521 Raji B cells were loaded with 500 nM calcein-AM (Life Technology, Waltham,
522 Massachusetts, USA) in AIM V medium (ThermoFisher Scientific, Waltham, Massachusetts,
523 USA) with 10 mM Hepes at room temperature for 15 min, washed and plated in 96-well
524 black plates with clear bottom (BD Falcon, Corning, New York, USA). BI2536-treated or
525 PLK1 KD CTLs and controls were added at different ratios to 0.5×10^4 settled target cells per
526 well to measure killing at 37°C, 5% CO₂. Triton X-100 (1%) was added to target cells alone
527 to calculate maximal target cell lysis as control. Target cell lysis was measured every 10 min
528 for 4 h. The decreased calcein fluorescence in target cells due to cell lysis was measured at
529 485 nm excitation wavelength and 528 nm emission wavelength in the bottom reading mode
530 using a Synergy HTX multi-mode plate reader (BioTek, Santa Clara, California, USA). The
531 fluorescence for the experimental condition was adjusted by the parameter γ according to
532 the live target cell control fluorescence. The γ value was measured at time zero: $\gamma =$
533 $F_{\text{live}}(0)/F_{\text{exp}}(0)$. Cytotoxicity was calculated based on the loss of calcein fluorescence in target
534 cells using the equation: % target cell lysis = $(F_{\text{live}} - \gamma \times F_{\text{exp}})/(F_{\text{live}} - F_{\text{lyse}}) \times 100$, where F_{live} is
535 the fluorescence of target cells alone, F_{exp} are CTL+APC samples and F_{lyse} is the maximal
536 target cell lysis. All the experiments were performed in duplicate and averaged to obtain one
537 dataset. The maximal CTL-induced target cell killing was assigned to the higher CTL:APC
538 ratio, on which the relative values for the other samples were based (Chang et al., 2018).

539

540 **Statistics and reproducibility**

541 Each experiment is the result of at least 3 independent replicates. The number of cells
542 analysed is specified in the figure legends. Statistical analyses were performed using Prism
543 software (GraphPad Software). Pairwise or multiple comparisons of values with normal
544 distribution were carried out using Student's t-test (unpaired), one-sample t-test (theoretical
545 mean=1) and one-way ANOVA, whereas values without Gaussian distribution were
546 analysed with Mann-Whitney test or Kruskal-Wallis test. Statistical significance was defined
547 as: **** $P \leq 0.0001$; *** $P \leq 0.001$; ** $P \leq 0.01$; * $P \leq 0.05$; n.s., not significant.

548

549 **Table T1. List of the primary antibodies used in this work**

550

Antibody (anti-)	Host species	Company	Catalog number	Dilution WB	Dilution IF
Actin	mouse	Millipore (Burlington, Massachusetts, USA)	MAB1501	1:10,000	-
Aurora-A	rabbit	Cell signalling (Danvers, Massachusetts, USA)	14475	-	1:100
CD3 ζ	mouse	Santa Cruz (California, USA)	sc-1239	-	1:200
pErk1/2 (T202/Y204)	rabbit	Cell signalling (Danvers, Massachusetts, USA)	9101	1:1,000	-
Granzyme B-488	mouse	Bio Legend (San Diego, California, USA)	560211	-	1:20
pLat (Y191)	rabbit	Cell signalling (Danvers, Massachusetts, USA)	3584S	1:1,000	-
Lck	mouse	BD (Franklin Lakes, New Jersey, USA)	610097	-	1:50
pLck (Y394)	mouse	Bio-technie (Minneapolis, Minnesota, USA)	MAB7500	1:1000	1:50

PCM1	mouse	Santa Cruz (California, USA)	sc-398365	-	1:300
Pericentrin	rabbit	Abcam (Cambridge, UK)	ab4448	-	1:200
PLK1	rabbit	Bio-technie (Minneapolis, Minnesota, USA)	104302	1:500	1:300
pPLK1 (S137)	rabbit	Abcam (Cambridge, UK)	ab21738	1:1,000	1:300
α -tubulin	mouse	Santa Cruz (California, USA)	sc-32293	-	1:500
γ -tubulin	mouse	Sigma-Aldrich (St. Louis, Missouri, USA)	T6557	-	1:200

551

552 **Acknowledgements**

553 The authors wish to thank Giuliano Callaini for critical reading of the manuscript and
554 Annamaria Fusillo for technical assistance.

555

556 **Competing interests**

557 The authors declare no competing financial interests.

558

559 **Funding**

560 This research has received funding from the European Commission (ERC_2021_SyG
561 951329 - ATTACK) to CTB and SV and AIRC (IG 2017-20148) to CTB.

562

563 **Data availability**

564 Data generated in this study are available upon request from corresponding author FF.

565 **References**

566

567 Andrés-Delgado, L., Antón, O.M., Alonso, M.A., 2013. Centrosome Polarization in T Cells:
568 A Task for Formins. *Front. Immunol.* 4. <https://doi.org/10.3389/fimmu.2013.00191>

569

570 Bálint, Š., Müller, S., Fischer, R., Kessler, B.M., Harkiolaki, M., Valitutti, S., Dustin, M.L.,
571 2020. Supramolecular attack particles are autonomous killing entities released from
572 cytotoxic T cells. *Science* 368, 897-901. <https://doi.org/10.1126/science.aay9207>.

573

574 Banerjee, P.P., Pandey, R., Zheng, R., Suhoski, M.M., Monaco-Shawver, L., Orange, J.S.,
575 2007. Cdc42-interacting protein-4 functionally links actin and microtubule networks at the
576 cytolytic NK cell immunological synapse. *J. Exp. Med.* 204, 2305–2320.
577 <https://doi.org/10.1084/jem.20061893>

578

579 Bertrand, F., Müller, S., Roh, K.-H., Laurent, C., Dupré, L., Valitutti, S., 2013. An initial and
580 rapid step of lytic granule secretion precedes microtubule organizing center polarization at
581 the cytotoxic T lymphocyte/target cell synapse. *Proc. Natl. Acad. Sci. U.S.A.* 110, 6073–
582 6078. <https://doi.org/10.1073/pnas.1218640110>

583

584 Bischoff, J.R., 1998. A homologue of *Drosophila* aurora kinase is oncogenic and amplified
585 in human colorectal cancers. *EMBO J* 17, 3052–3065.
586 <https://doi.org/10.1093/emboj/17.11.3052>

587

588 Blas-Rus, N., Bustos-Morán, E., Pérez De Castro, I., De Cárcer, G., Borroto, A., Camafeita,
589 E., Jorge, I., Vázquez, J., Alarcón, B., Malumbres, M., Martín-Cófreces, N.B., Sánchez-
590 Madrid, F., 2016. Aurora A drives early signalling and vesicle dynamics during T-cell
591 activation. *Nat Commun* 7, 11389. <https://doi.org/10.1038/ncomms11389>

592

593 Bouchet, J., Del Río-Iñiguez, I., Lasserre, R., Agüera-Gonzalez, S., Cuche, C., Danckaert,
594 A., McCaffrey, M.W., Di Bartolo, V., Alcover, A., 2016. Rac1-Rab11- FIP 3 regulatory hub
595 coordinates vesicle traffic with actin remodeling and T-cell activation. *EMBO J* 35, 1160–
596 1174. <https://doi.org/10.15252/emboj.201593274>

597

- 598 Bruinsma, W., Macůrek, L., Freire, R., Lindqvist, A., Medema, R.H., 2013. Bora and Aurora-
599 A continue to activate Plk1 in mitosis. *J. Cell Sci.* jcs.137216.
600 <https://doi.org/10.1242/jcs.137216>
601
- 602 Budde, P.P., Kumagai, A., Dunphy, W.G., Heald, R., 2001. Regulation of Op18 during
603 Spindle Assembly in *Xenopus* Egg Extracts. *J. Cell Biol.* 153, 149–158.
604 <https://doi.org/10.1083/jcb.153.1.149>
605
- 606 Bunnell, S.C., Hong, D.I., Kardon, J.R., Yamazaki, T., McGlade, C.J., Barr, V.A., Samelson,
607 L.E., 2002. T cell receptor ligation induces the formation of dynamically regulated signaling
608 assemblies. *J. Cell Biol.* 158, 1263–1275. <https://doi.org/10.1083/jcb.200203043>
609
- 610 Calvo, V., Izquierdo, M., 2021. Role of Actin Cytoskeleton Reorganization in Polarized
611 Secretory Traffic at the Immunological Synapse. *Front. Cell Dev. Biol.* 9, 629097.
612 <https://doi.org/10.3389/fcell.2021.629097>
613
- 614 Cassioli, C., Baldari, C.T., 2022. The Expanding Arsenal of Cytotoxic T Cells. *Front.*
615 *Immunol.* 13, 883010. <https://doi.org/10.3389/fimmu.2022.883010>
616
- 617 Cassioli, C., Onnis, A., Finetti, F., Capitani, N., Brunetti, J., Compeer, E.B., Niederlova, V.,
618 Stepanek, O., Dustin, M.L., Baldari, C.T., 2021. The Bardet–Biedl syndrome complex
619 component BBS1 controls T cell polarity during immune synapse assembly. *J. Cell Sci.* 134,
620 jcs258462. <https://doi.org/10.1242/jcs.258462>
621
- 622 Chang, H.-F., Mannebach, S., Beck, A., Ravichandran, K., Krause, E., Frohnweiler, K.,
623 Fecher-Trost, C., Schirra, C., Pattu, V., Flockerzi, V., Rettig, J., 2018. Cytotoxic granule
624 endocytosis depends on the Flower protein. *J. Cell Biol.* 217, 667–683.
625 <https://doi.org/10.1083/jcb.201706053>
626
- 627 Chang, H.F., Schirra, C., Ninov, M., Hahn, U., Ravichandran, K., Krause, E., Becherer, U.,
628 Bálint, Š., Harkiolaki, M., Urlaub, H., Valitutti, S., Baldari, C.T., Dustin, M.L., Jahn, R., Rettig,
629 J., 2022. Identification of distinct cytotoxic granules as the origin of supramolecular attack
630 particles in T lymphocytes. *Nat. Commun.* 13, 1029. <https://doi.org/10.1038/s41467-022-28596-y>
631

632

633 Colicino, E.G., Hehnly, H., 2018. Regulating a key mitotic regulator, polo-like kinase 1
634 (PLK1). *Cytoskeleton* 75, 481–494. <https://doi.org/10.1002/cm.21504>

635

636 Das, V., Thoulouze, M.-I., Galli, T., Roux, P., Dautry-Varsat, A., Alcover, A., 2004.
637 Activation-Induced Polarized Recycling Targets T Cell Antigen Receptors to the
638 Immunological Synapse: Involvement of SNARE Complexes. *Immunity* 20, 577-588.

639

640 De La Roche, M., Asano, Y., Griffiths, G.M., 2016. Origins of the cytolytic synapse. *Nat. Rev.*
641 *Immunol.* 16, 421–432. <https://doi.org/10.1038/nri.2016.54>

642

643 De La Roche, M., Ritter, A.T., Angus, K.L., Dinsmore, C., Earnshaw, C.H., Reiter, J.F.,
644 Griffiths, G.M., 2013. Hedgehog Signaling Controls T Cell Killing at the Immunological
645 Synapse. *Science* 342, 1247–1250. <https://doi.org/10.1126/science.1244689>

646

647 Dixit, R., Ross, J.L., 2010. Studying Plus-End Tracking at Single Molecule Resolution Using
648 TIRF Microscopy, in: *Methods in Cell Biology*. Elsevier, pp. 543–554.
649 [https://doi.org/10.1016/S0091-679X\(10\)95027-9](https://doi.org/10.1016/S0091-679X(10)95027-9)

650

651 Douanne, T., Griffiths, G.M., 2021. Cytoskeletal control of the secretory immune synapse.
652 *Curr. Opin. Cell Biol.* 71, 87–94. <https://doi.org/10.1016/j.ceb.2021.02.008>

653

654 Filbert, E.L., Le Borgne, M., Lin, J., Heuser, J.E., Shaw, A.S., 2012. Stathmin Regulates
655 Microtubule Dynamics and Microtubule Organizing Center Polarization in Activated T Cells.
656 *J. Immunol.* 188, 5421–5427. <https://doi.org/10.4049/jimmunol.1200242>

657

658 Gomez, T.S., Billadeau, D.D., 2008. T Cell Activation and the Cytoskeleton: You Can't Have
659 One Without the Other, in: *Advances in Immunology*. Elsevier, pp. 1–64.
660 [https://doi.org/10.1016/S0065-2776\(08\)00001-1](https://doi.org/10.1016/S0065-2776(08)00001-1).

661

662 Gorman, J.A., Babich, A., Dick, C.J., Schoon, R.A., Koenig, A., Gomez, T.S., Burkhardt,
663 J.K., Billadeau, D.D., 2012. The Cytoskeletal Adaptor Protein IQGAP1 Regulates TCR-
664 Mediated Signaling and Filamentous Actin Dynamics. *J. Immunol.* 188, 6135–6144.
665 <https://doi.org/10.4049/jimmunol.1103487>

666

667 Green, D.R., Llambi F., 2015. Cell Death Signaling. *Cold Spring Harb. Perspect. Biol.* 7,
668 a006080. <https://doi.org/10.1101/cshperspect.a006080>

669

670 Gutteridge, R.E.A., Ndiaye, M.A., Liu, X., Ahmad, N., 2016. Plk1 Inhibitors in Cancer
671 Therapy: From Laboratory to Clinics. *Mol. Cancer Ther.* 15, 1427–1435.
672 <https://doi.org/10.1158/1535-7163.MCT-15-0897>

673

674 Higaki, T., Kutsuna, N., Sano, T., Kondo, N., Hasezawa, S., 2010. Quantification and cluster
675 analysis of actin cytoskeletal structures in plant cells: role of actin bundling in stomatal
676 movement during diurnal cycles in *Arabidopsis* guard cells. *Plant J.* 61, 156–165.
677 <https://doi.org/10.1111/j.1365-313X.2009.04032.x>

678

679 Higaki, T., 2017. Quantitative evaluation of cytoskeletal organizations by microscopic image
680 analysis. *Plant Morphol.* 29, 15–21. <https://doi.org/10.5685/plmorphol.29.15>

681

682 Hooikaas, P.J., Damstra, H.G., Gros, O.J., Van Riel, W.E., Martin, M., Smits, Y.T., Van
683 Loosdregt, J., Kapitein, L.C., Berger, F., Akhmanova, A., 2020. Kinesin-4 KIF21B limits
684 microtubule growth to allow rapid centrosome polarization in T cells. *eLife* 9, e62876.
685 <https://doi.org/10.7554/eLife.62876>

686

687 Huse, M., 2012. Microtubule-organizing center polarity and the immunological synapse:
688 protein kinase C and beyond. *Front. Immun.* 3. <https://doi.org/10.3389/fimmu.2012.00235>

689

690 Huse, M., Le Floc'h, A., Liu, X., 2013. From lipid second messengers to molecular motors:
691 microtubule-organizing center reorientation in T cells. *Immunol. Rev.* 256, 95–106.
692 <https://doi.org/10.1111/imr.12116>

693

694 Ilani, T., Khanna, C., Zhou, M., Veenstra, T.D., Bretscher, A., 2007. Immune synapse
695 formation requires ZAP-70 recruitment by ezrin and CD43 removal by moesin. *J. Cell Biol.*
696 179, 733–746. <https://doi.org/10.1083/jcb.200707199>

697

698 Iliaki, S., Beyaert, R., Afonina, I.S., 2021. Polo-like kinase 1 (PLK1) signaling in cancer and
699 beyond. *Biochem. Pharmacol.* 193, 114747. <https://doi.org/10.1016/j.bcp.2021.114747>

700

701 Jenkins, M.R., Stinchcombe, J.C., Au-Yeung, B.B., Asano, Y., Ritter, A.T., Weiss, A.,
702 Griffiths, G.M., 2014. Distinct structural and catalytic roles for Zap70 in formation of the
703 immunological synapse in CTL. *eLife* 3, e01310. <https://doi.org/10.7554/eLife.01310>

704

705 Johmura, Y., Soung, N.-K., Park, J.-E., Yu, L.-R., Zhou, M., Bang, J.K., Kim, B.-Y., Veenstra,
706 T.D., Erikson, R.L., Lee, K.S., 2011. Regulation of microtubule-based microtubule
707 nucleation by mammalian polo-like kinase 1. *Proc. Natl. Acad. Sci. U.S.A.* 108, 11446–
708 11451. <https://doi.org/10.1073/pnas.1106223108>

709

710 Joukov, V., De Nicolo, A., 2018. Aurora-PLK1 cascades as key signaling modules in the
711 regulation of mitosis. *Sci. Signal.* 11, eaar4195. <https://doi.org/10.1126/scisignal.aar4195>

712 Kabanova, A., Zurli, V., Baldari, C.T., 2018. Signals Controlling Lytic Granule Polarization
713 at the Cytotoxic Immune Synapse. *Front. Immunol.* 9, 307.
714 <https://doi.org/10.3389/fimmu.2018.00307>

715

716 Kuhn, J.R., Poenie, M., 2002. Dynamic Polarization of the Microtubule Cytoskeleton during
717 CTL-Mediated Killing. *Immunity* 16, 111–121. [https://doi.org/10.1016/S1074-
718 7613\(02\)00262-5](https://doi.org/10.1016/S1074-7613(02)00262-5)

719

720 Kuhné, M.R., Lin, J., Yablonski, D., Mollenauer, M.N., Ehrlich, L.I.R., Huppa, J., Davis, M.M.,
721 Weiss, A., 2003. Linker for Activation of T Cells, ζ -Associated Protein-70, and Src Homology
722 2 Domain-Containing Leukocyte Protein-76 are Required for TCR-Induced Microtubule-
723 Organizing Center Polarization. *J. Immunol.* 171, 860–866.
724 <https://doi.org/10.4049/jimmunol.171.2.860>

725

726 Lénárt, P., Petronczki, M., Steegmaier, M., Di Fiore, B., Lipp, J.J., Hoffmann, M., Rettig,
727 W.J., Kraut, N., Peters, J.-M., 2007. The Small-Molecule Inhibitor BI 2536 Reveals Novel
728 Insights into Mitotic Roles of Polo-like Kinase 1. *Curr. Biol.* 17, 304–315.
729 <https://doi.org/10.1016/j.cub.2006.12.046>

730

731 Li, R., Gundersen, G.G., 2008. Beyond polymer polarity: how the cytoskeleton builds a
732 polarized cell. *Nat. Rev. Mol. Cell. Biol.* 9, 860–873. <https://doi.org/10.1038/nrm2522>

733

- 734 Liu, X., Kapoor, T.M., Chen, J.K., Huse, M., 2013. Diacylglycerol promotes centrosome
735 polarization in T cells via reciprocal localization of dynein and myosin II. *Proc. Natl. Acad.*
736 *Sci. U.S.A.* 110, 11976–11981. <https://doi.org/10.1073/pnas.1306180110>
737
- 738 Lowin-Kropf, B., Shapiro, V.S., Weiss, A., 1998. Cytoskeletal Polarization of T Cells Is
739 Regulated by an Immunoreceptor Tyrosine-based Activation Motif–dependent Mechanism.
740 *J. Cell Biol.* 140, 861–871. <https://doi.org/10.1083/jcb.140.4.861>
741
- 742 McKenzie, B., Valitutti, S., 2023. Resisting T cell attack: tumor-cell-intrinsic defense and
743 reparation mechanisms. *Trends Cancer* 9, 198-211. <https://doi.org/10.1016/j.trecan.2022.12.003>
744
745
- 746 Manders, E.M.M., Stap, J., Brakenhoff, G.J., Driel, R.V., Aten, J.A., 1992. Dynamics of
747 three-dimensional replication patterns during the s-phase, analysed by double labelling of
748 dna and confocal microscopy. *J. Cell Sci.* 103, 857–862.
749 <https://doi.org/10.1242/jcs.103.3.857>
750
- 751 Martín-Cófreces, N.B., Baixauli, F., López, M.J., Gil, D., Monjas, A., Alarcón, B., Sánchez-
752 Madrid, F., 2012a. End-binding protein 1 controls signal propagation from the T cell receptor:
753 EB1 regulates TCR signalling. *EMBO J.* 31, 4140–4152.
754 <https://doi.org/10.1038/emboj.2012.242>
755
- 756 Moriwaki, T., Goshima, G., 2016. Five factors can reconstitute all three phases of
757 microtubule polymerization dynamics. *J. Cell Biol.* 215, 357–368.
758 <https://doi.org/10.1083/jcb.201604118>
759
- 760 Nehlig, A., Molina, A., Rodrigues-Ferreira, S., Honoré, S., Nahmias, C., 2017. Regulation of
761 end-binding protein EB1 in the control of microtubule dynamics. *Cell. Mol. Life Sci.* 74, 2381–
762 2393. <https://doi.org/10.1007/s00018-017-2476-2>
763
- 764 Ohta, M., Zhao, Z., Wu, D., Wang, S., Harrison, J.L., Gómez-Cavazos, J.S., Desai, A.,
765 Oegema, K.F., 2021. Polo-like kinase 1 independently controls microtubule-nucleating
766 capacity and size of the centrosome. *J. Cell Biol.* 220, e202009083.
767 <https://doi.org/10.1083/jcb.202009083>

768

769 Onnis, A., Andreano, E., Cassioli, C., Finetti, F., Della Bella, C., Staufer, O., Pantano, E.,
770 Abbiento, V., Marotta, G., D'Elisos, M.M., Rappuoli, R., Baldari, C.T., 2023. SARS-CoV-2
771 Spike protein suppresses CTL-mediated killing by inhibiting immune synapse assembly. *J.*
772 *Exp. Med.* 220, e20220906. <https://doi.org/10.1084/jem.20220906>

773

774 Park, J.-E., Kim, T.-S., Kim, B.Y., Lee, K.S., 2015. Selective blockade of cancer cell
775 proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal
776 inhibition of its polo-box domain. *Cell Cycle* 14, 3624–3634.
777 <https://doi.org/10.1080/15384101.2015.1104435>

778

779 Pathni, A., Özçelikkale, A., Rey-Suarez, I., Li, L., Davis, S., Rogers, N., Xiao, Z., Upadhyaya,
780 A., 2022. Cytotoxic T Lymphocyte Activation Signals Modulate Cytoskeletal Dynamics and
781 Mechanical Force Generation. *Front. Immunol.* 13, 779888.
782 <https://doi.org/10.3389/fimmu.2022.779888>

783

784 Rashid, A., Naaz, A., Rai, A., Chatterji, B.P., Panda, D., 2020. Inhibition of polo-like kinase
785 1 suppresses microtubule dynamics in MCF-7 cells. *Mol. Cell. Biochem.* 465, 27–36.
786 <https://doi.org/10.1007/s11010-019-03664-y>

787

788 Ritter, A.T., Asano, Y., Stinchcombe, J.C., Dieckmann, N.M.G., Chen, B.-C., Gawden-Bone,
789 C., van Engelenburg, S., Legant, W., Gao, L., Davidson, M.W., Betzig, E., Lippincott-
790 Schwartz, J., Griffiths, G.M., 2015. Actin Depletion Initiates Events Leading to Granule
791 Secretion at the Immunological Synapse. *Immunity* 42, 864–876.
792 <https://doi.org/10.1016/j.immuni.2015.04.013>

793

794 Rossy, J., Williamson, D.J., Gaus, K., 2012. How does the kinase Lck phosphorylate the T
795 cell receptor? Spatial organization as a regulatory mechanism. *Front. Immunol.* 3.
796 <https://doi.org/10.3389/fimmu.2012.00167>

797

798 Samelson, L.E., 2002. Signal Transduction Mediated by the T Cell Antigen Receptor: The
799 Role of Adapter Proteins. *Annu. Rev. Immunol.* 20, 371–394.
800 <https://doi.org/10.1146/annurev.immunol.20.092601.111357>

801

- 802 Sanchez, E., Liu, X., Huse, M., 2019. Actin clearance promotes polarized dynein
803 accumulation at the immunological synapse. *PLoS ONE* 14, e0210377.
804 <https://doi.org/10.1371/journal.pone.0210377>
805
- 806 Sardon, T., Peset, I., Petrova, B., Vernos, I., 2008. Dissecting the role of Aurora A during
807 spindle assembly. *EMBO J* 27, 2567–2579. <https://doi.org/10.1038/emboj.2008.173>
808
- 809 Serrador, J.M., Cabrero, J.R., Sancho, D., Mittelbrunn, M., Urzainqui, A., Sánchez-Madrid,
810 F., 2004. HDAC6 Deacetylase Activity Links the Tubulin Cytoskeleton with Immune Synapse
811 Organization. *Immunity* 20, 417–428. [https://doi.org/10.1016/S1074-7613\(04\)00078-0](https://doi.org/10.1016/S1074-7613(04)00078-0)
812
- 813 Soares, H., Lasserre, R., Alcover, A., 2013. Orchestrating cytoskeleton and intracellular
814 vesicle traffic to build functional immunological synapses. *Immunol. Rev.* 256, 118–132.
815 <https://doi.org/10.1111/imr.12110>
816
- 817 Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krššák, M., Gürtler, U.,
818 Garin-Chesa, P., Lieb, S., Quant, J., Grauert, M., Adolf, G.R., Kraut, N., Peters, J.-M., Rettig,
819 W.J., 2007. BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor
820 Growth In Vivo. *Curr. Biol.* 17, 316–322. <https://doi.org/10.1016/j.cub.2006.12.037>
821
- 822 Štefanová, I., Hemmer, B., Vergelli, M., Martin, R., Biddison, W.E., Germain, R.N., 2003.
823 TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative
824 feedback pathways. *Nat. Immunol.* 4, 248–254. <https://doi.org/10.1038/ni895>
825
- 826 Stinchcombe, J.C., Griffiths, G.M., 2014. Communication, the centrosome and the
827 immunological synapse. *Phil. Trans. R. Soc. B* 369, 20130463.
828 <https://doi.org/10.1098/rstb.2013.0463>
829
- 830 Strebhardt, K., 2010. Multifaceted polo-like kinases: drug targets and antitargets for cancer
831 therapy. *Nat. Rev. Drug Discov.* 9, 643–660. <https://doi.org/10.1038/nrd3184>
832
- 833 Su, S., Chhabra, G., Singh, C.K., Ndiaye, M.A., Ahmad, N., 2022. PLK1 inhibition-based
834 combination therapies for cancer management. *Trans. Oncol.* 16, 101332.
835 <https://doi.org/10.1016/j.tranon.2021.101332>

836

837 Tsun, A., Qureshi, I., Stinchcombe, J.C., Jenkins, M.R., De La Roche, M., Kleczkowska, J.,
838 Zamoyska, R., Griffiths, G.M., 2011. Centrosome docking at the immunological synapse is
839 controlled by Lck signaling. *J. Cell Biol.* 192, 663–674.
840 <https://doi.org/10.1083/jcb.201008140>

841

842 Wang, G., Chen, Q., Zhang, X., Zhang, B., Zhuo, X., Liu, J., Jiang, Q., Zhang, C., 2013.
843 PCM1 Recruits Plk1 to Pericentriolar Matrix to Promote Primary Cilia Disassembly before
844 Mitotic Entry. *J. Cell Sci.* jcs.114918. <https://doi.org/10.1242/jcs.114918>

845

846 Zeidan, A.M., Ridinger, M., Lin, T.L., Becker, P.S., Schiller, G.J., Patel, P.A., Spira, A.I.,
847 Tsai, M.L., Samuëlsz, E., Silberman, S.L., Erlander, M., Wang, E.S., 2020. A Phase Ib Study
848 of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with
849 Relapsed or Refractory Acute Myeloid Leukemia. *Clin. Cancer Res.* 26, 6132–6140.
850 <https://doi.org/10.1158/1078-0432.CCR-20-2586>

851

852 Zitouni, S., Nabais, C., Jana, S.C., Guerrero, A., Bettencourt-Dias, M., 2014. Polo-like
853 kinases: structural variations lead to multiple functions. *Nat. Rev. Mol. Cell. Biol.* 15, 433–
854 452. <https://doi.org/10.1038/nrm3819>

855

856 Zyss, D., Ebrahimi, H., Gergely, F., 2011. Casein kinase I delta controls centrosome
857 positioning during T cell activation. *J. Cell Biol.* 195, 781–797.
858 <https://doi.org/10.1083/jcb.201106025>

859

860 **Figure legends**

861

862 **Figure 1. PLK1 is recruited to and phosphorylated at the IS in CTLs. (A)** Immunoblot
863 analysis with anti-PLK1 antibody of lysates of CD8⁺ T cells collected at days 0, 5 or 7
864 following stimulation with anti-CD3/CD28 coated beads. A control anti-actin blot of the
865 stripped filter is shown below. The migration of molecular mass markers is indicated. The
866 quantification of PLK1 in CTL lysates is reported in the graph (n=4, mean fold \pm SD;
867 ANOVA). **(B)** Quantification using Mander's coefficient of the weighted colocalization of
868 PLK1 and the centrosome markers PCM1 or γ -tubulin in CTLs (30 cells/sample, n=3; mean
869 fold \pm SD). Medial optical sections of representative images are shown. Scale bar: 5 μ m. **(C)**
870 Immunofluorescence analysis of PLK1 and PCM1 5 or 15 minutes after conjugate formation
871 of CTLs and SAg-loaded Raji cells. Conjugates formed in the absence of SAGs (no SAGs)
872 were used as negative control. Scale bar: 5 μ m. The graphs show the percentage of
873 conjugates with PLK1 polarization at the IS (15 cells/sample, n=3; ANOVA)(left) and the
874 quantification of the distance of PLK1 from the IS membrane (μ m)(20 cells/sample, n=3;
875 Kurskall Wallis test)(right), respectively. **(D)** Immunoblot analysis with anti-pPLK1 antibody
876 of lysates of CTLs either unstimulated or stimulated with anti-CD3 mAb for the indicated
877 times. A control anti-actin blot of the stripped filter is shown below. The migration of
878 molecular mass markers is indicated. The quantification of pPLK1 in anti-CD3 mAb-
879 stimulated or unstimulated CTLs is reported in the graph (n=3, mean fold \pm SD; one sample
880 t test). **(E)** Immunofluorescence analysis of p-PLK1 and PCM1 5 or 15 minutes after
881 conjugate formation of CTLs and SAg-pulsed Raji B cells. Scale bar: 5 μ m. The graphs show
882 the percentage of conjugates harbouring accumulation of the phosphorylated form of PLK1
883 at the IS region (15 cells/sample, n=3; mean \pm SD, ANOVA)(left), the quantification of pPLK1
884 intensity at the IS membrane *versus* the total cell membrane (center) and the quantification
885 of pPLK1 fluorescence intensity in the centrosome region defined from the point of PCM1
886 maximal intensity (24 cells/sample, n=3; mean \pm SD, Kurskall Wallis test)(right). *P < 0.05;
887 **P < 0.01; ***P < 0.001; ****P < 0.0001.

888

889 **Figure 2. PLK1 inhibition or depletion impairs TCR clustering at the IS in CTLs. (A)**
890 Immunofluorescence analysis of the TCR subunit CD3 ζ in 5 or 15 minutes conjugates of
891 control (vehicle) and BI2536-treated CTLs and SAg-loaded Raji cells. Representative
892 images of medial optical sections are shown. Scale bar: 5 μ m. The histograms show the
893 quantification of the percentages of conjugates positive for CD3 ζ polarization to the IS (top)

894 and the quantification of the relative CD3 ζ fluorescence intensity at the IS (bottom)(20
895 cells/sample, $n \geq 3$; ANOVA). **(B)** Immunoblot analysis of PLK1 in representative matched
896 control (scramble RNAi) and PLK1 KD CTLs, with respective loading control (actin) is
897 shown. The migration of molecular mass markers is indicated. The quantification of PLK1 in
898 CTL lysates is reported in the table ($n=3$; mean fold \pm SD, one sample t test). **(C)**
899 Quantification of the immunofluorescence analysis of 5 or 15 minutes conjugates of control
900 and PLK1 KD CTLs and SAg-loaded Raji cells. The histograms show the percentages of
901 conjugates positive for CD3 ζ polarization to the IS (left) and the quantification of the relative
902 CD3 ζ fluorescence intensity at the IS (right) (10 cells/sample, $n=3$; ANOVA). * $P < 0.05$; ** P
903 < 0.01 ; *** $P < 0.001$; **** $P < 0.0001$.

904

905 **Figure 3. PLK1 inhibition impairs TCR signalling in CTLs.** **(A)** Immunofluorescence
906 analysis of the phosphorylated active form of Lck (Y394) (pLck394) in 5 or 15 minutes
907 conjugates of control (vehicle) or BI2536-treated CTLs and SAg-loaded Raji cells.
908 Representative images of medial optical sections are shown. Scale bar: 5 μ m. The
909 histograms show the quantification of the percentages of conjugates positive for pLck394
910 polarization to the IS (top) and the quantification of the relative pLck394 fluorescence
911 intensity at the IS (bottom) (10 cells/sample, $n \geq 3$; ANOVA). **(B,C)** Immunoblot analysis with
912 anti-pLck394 (B), anti-pLAT and anti-pErk1/2 (C) antibodies of lysates of either control or
913 BI2536-treated CTLs, unstimulated or stimulated with anti-CD3 mAb for the indicated times.
914 A control anti-actin blot of the stripped filter is shown below. The migration of molecular mass
915 markers is indicated. The graphs show the quantification of pLck394 (B), pErk1/2 and pLAT
916 (C), respectively ($n \geq 3$; mean fold \pm SD, one-way ANOVA). * $P < 0.05$; ** $P < 0.01$; *** $P <$
917 0.001 ; **** $P < 0.0001$.

918

919 **Figure 4. PLK1 inhibition impairs centrosome and LG polarization to the IS in CTLs.**
920 **(A)** Immunofluorescence analysis of the centrosomal protein pericentrin (PCNT-1) and the
921 LG component granzyme B (GzmB) in 5 and 15 minutes conjugates of vehicle- and BI2536-
922 treated CTLs and SAg-pulsed Raji cells. Medial optical sections of representative images
923 are shown. Scale bar: 5 μ m. **(B,E)** Quantification of the percentages of conjugates positive
924 for PCNT-1 at the IS (left) and of the distance of the centrosome from the synaptic
925 membrane (right) (μ m) in conjugates of control or BI2536-treated CTLs and Raji B cells (B)
926 or of control and PLK1 KD CTLs (E). **(C,F)** Quantification of the percentages of conjugates
927 positive for GzmB at the IS (top (C), left (F)) and of the mean distance of single GzmB⁺

928 vesicles from the synaptic membrane (bottom (C), right (F)) (μm) in individual conjugates of
929 control or BI2536-treated CTLs (C), or of control and PLK1 KD CTLs (F) and Raji B cells.
930 **(D,G)** Quantification of the mean distance of single GzmB⁺ vesicles from the centrosome in
931 individual conjugates of control and either BI2536-treated (D) or PLK1 KD (G) CTLs and Raji
932 B cells (μm). Data are reported as mean \pm SD. Statistical analysis: B-D: 20 cells/sample,
933 $n \geq 3$; E-G: 10 cells/sample, $n=3$; ANOVA. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$.

934

935 **Figure 5. PLK1 inhibition impairs microtubule dynamics in CTLs. (A,B)**
936 Immunofluorescence analysis of α -tubulin in control and BI2536-treated CTLs.
937 Representative images of maximum intensity projections of z-stacks are shown. Scale bar:
938 10 μm . **(A)** The arrowhead points to an example of cell displaying microtubules organized
939 in few and thick α -tubulin-decorated bundles, while the arrow points to a cell showing
940 microtubule bundles originating from the cortical area. The graph shows the percentage of
941 cells displaying thick microtubule bundles ($n=3$; mean fold \pm SD, t test). **(B)** Profiles of
942 fluorescence intensity along a manually-selected line (white bar) in representative control or
943 BI2536 treated CTLs. **(C)** Skewness of α -tubulin intensity distribution in control and BI2536-
944 treated CTLs (≥ 40 cells from 3 independent experiments; mean fold \pm SD, t test). **(D)**
945 Imaging of EB1-EGFP-expressing CTLs, pre-treated with DMSO or BI2536 and plated on
946 anti-CD3/CD28-coated glass-bottom chambers. Representative projections of time lapse
947 are shown ($\Delta t = 45$ sec). Images were taken every 300 ms for 3 minutes using a TIRF
948 microscope. Scale bar: 5 μm . **(E)** Representative polar graphs of images in panel D showing
949 the trajectories (left) and the speed (right) of EB1-EGFP-decorated microtubule (+) tips
950 showing, respectively, the projection of object movements (color path length corresponds to
951 track length) and the heading of each object as a color arrow (length corresponds to object
952 speed). The external circle in the polar graphs indicates a distance of 2.8 μm (left) or a speed
953 of 0.8 $\mu\text{m/s}$ (right). **(F)** Quantification of the number (left) and length (center) of segments,
954 and the speed of the growing tracks (right), reported as average value per cell (≥ 32 cells
955 from 3 independent experiments; mean fold \pm SD, t test). * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$;
956 **** $P < 0.0001$.

957

958 **Figure 6. PLK1 inhibition impairs CTL-mediated killing. (A,B)** Real-time calcein release-
959 based killing assay. CTLs either untreated or pre-treated with BI2536 (A) and control or
960 PLK1 KD CTLs (B), were co-cultured with SAg-loaded Raji B cells at the target:CTL ratios
961 indicated, and target cell killing was measured every 10 minutes for 4 hours as reported in

962 the kinetic graph (left). Quantification of the percentage of target cell death at the endpoint
963 of the procedure (4 h) is shown on the right graph. The data refer to at least three
964 independent experiments performed in duplicate and are reported as mean fold \pm SD, with
965 target cell lysis at the highest target:CTL ratio of the control sample set at 100% of
966 cytotoxicity (ANOVA). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.




Figure 1




Figure 2






Figure 3


A




C




B




D



E



G



F




Figure 4




Figure 5




Figure 6